In this episode of the a16z Podcast introduced by Vijay Pande (based on a presentation at our summit event), Russ Altman, Stanford professor of bioengineering -- and former chairman of their Bioengineering Department -- takes us on a short but deep tour of the possibilities of genomics in drug discovery. Including how building a large bank of human genetic variations will change our understanding and optimization of drug response. Altman (who also hosts his own radio show, "The Future of Everything" on SiriusXM and Stanford radio) describes how in much the same way we inherit our grandmother's eyes, or our great grandfather's ears, we also inherit a response to certain drugs: whether they work or not, what side effects we'll experience, how we react to them. But it's not just genetics information that matters here; it's also molecular, cellular, tissue, and other data about the whole organism. By applying data science and bioinformatics on a more complete data "bank" like this, for the first time, we can see the whole range of actions and side effects -- as well as possible new uses -- that specific drugs will have on specific individuals. The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

Humans have always wanted to enhance themselves -- from getting nutrition just-right to optimizing their performance, whether in sports or health or work. And food is a big part of all that. But our current systems of food production (and consumption) are far from efficient and sustainable let alone optimizable. That's where a whole new generation of wearable/ bio-feedback, food and nutrition, food production, and performance enhancement/ "nootropics" companies come in. How do these approaches move from the internet and online communities into the mainstream? Or from the university lab to the field? Or, put yet another way, from hobby to daily practice? After all, what we measure, what we take in, and what we output defines what it means to be human. We discuss this "future of you" in this episode of the a16z podcast with Daniel Chao, CEO of Halo Neuroscience; Rob Rhinehart, CEO of Soylent; James Rogers, CEO of Apeel; and Geoffrey Woo, CEO of Nootrobox -- based on a conversation with Chris Dixon at our inaugural Summit event. The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.